Quinapril prevents hypertension and enhanced vascular reactivity in nitroarginine-treated rats

Blood Pressure

Volumn 6, Issue 2, 1997, Pages 117-124

  Charpie, John R ^a,b   Charpie, Peggy M ^a   Goud, Chetan ^a   Pitt, Bertram ^a   Webb, R Clinton ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Division of Cardiology CVC Cardiovascular Medicine   (United States)

Author keywords

angiotensin converting enzyme; endothelium; hypertension; nitric oxide synthase; vascular smooth muscle

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; QUINAPRIL;

ANIMAL EXPERIMENT; ARTICLE; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 0030897144     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059709061810     Document Type: Article

References (49)

1. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zats R. Chronic inhibition of nitric oxide synthesis, a new model of arterial hypertension. Hypertension 1992; 20: 298-303.
2. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-81.
3. Dananberg J, Sider RS, Grekin RJ. Sustained hypertension induced by orally administered nitro-L-arginine. Hypertension 1993; 21: 359-63.
4. Ward JE, Angus JA. Acute and chronic inhibition of nitric oxide synthase in conscious rabbits: role of nitric oxide in the control of vascular tone. J Cardiovasc Pharmacol 1993; 21: 804-14.
5. Manning R Jr, Hu L, Mizelle HL, Montani JP, Norton MW. Cardiovascular responses to long-term blockade of nitric oxide synthesis. Hypertension 1993; 22: 40-8.
6. GMethylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989; 160: 881-6.
7. G-nitroarginine in dogs. Am J Hypertens 1992; 5: 484-7.
8. G-Methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo: a role for nitric oxide in the central regulation of sympathetic tone? Circ Res 1992; 70: 607-11.
9. Togashi H, Sakuma I, Yoshioka M, et al. A central action of nitric oxide in blood pressure regulation. J Pharmacol Exp Ther 1992; 262: 343-7.
10. Harada S, Tokunaga S, Momohara M, et al. Inhibition of nitric oxide formation in the nucleus tractus solitarius. Circ Res 1993; 72: 511-6.
11. Tagawa T, Imaizumi T, Harada S, et al. Nitric oxide influences neuronal activity in the nucleus tractus solitarius of rat brainstem slices. Circ Res 1994; 75: 70-6.
12. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995; 26: 691-5.
13. Guyton AC. Long-term arterial blood pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol 1990; 259: R865-77.
14. Guyton AC, Coleman TG, Cowley AW Jr, Manning RD Jr, Norman RA Jr, Ferguson JD. A system analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ Res 1973; 35: 159-76.
15. DiBona G. The functions of the renal nerves. Rev Physiol Biochem Pharmacol 1982; 94: 75-181.
16. Manning RD Jr, Hu L, Mizelle HL, Granger JP. Role of nitric oxide in long-term angiotension II-induced renal vasoconstriction. Hypertension 1993; 21: 949-55.
17. Salazar JF, Alberola A, Pinilla JM, Romero C, Quesada T. Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension 1993; 22: 49-55.
18. Manning RD Jr, Hu L, Williamson TD. Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. Hypertension 1994; 23 (6 pt 2): 951-6.
19. Majid DSA, Williams A, Navar LG. Inhibition of nitric oxide synthesis attenuates pressure-induced natriuretic responses in anesthetized dogs. Am J Physiol 1992; 264: F79-87.
20. Granger J, Novak J, Schnackenberg C, Williams S, Reinhart GA. Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition. Hypertension 1996; 27 (part 2): 613-88.
21. Hropot M, Grotsch H, Klaus E, Langer KH, Linz W, Wiemer G, Scholkens BA. Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn Schmiedebergs Arch Pharmacol 1994; 350 (6): 646-52.
22. Matsuoka H, Nishida H, Nomura G, Van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 1994; 23 (part 2): 971-5.
23. G-nitro-L-arginine methyl ester in conscious Long Evans rats. Br J Pharmacol 1990; 101: 625-31.
24. Wang YX, Gravas I, Wierzba T, Lammek B, Gravas H. Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension 1992; 19 Suppl II: II-255-II-261.
25. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
26. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
27. Kung CF, Moreau P, Takase H, Luscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Hypertension 1995; 26: 744-51.
28. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990: 16: 532-40.
29. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
30. Novosel D, Lang M, Noll G, Luscher T. Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol 1994; 24: 979-85.
31. Dohi Y, Criscione L, Pfeiffer K, Luscher T. Angiotensin blockade or calcium antagonists normalize endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994; 24: 372-9.
32. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
33. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990; 70: 921-61.
34. Diez J. Cardiovascular growth associated with arterial hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl B: 1-5.
35. Delacretaz E, Hayoz D, Osterheld MC, Genton CY, Brunner HR, Waeber B. Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. Hypertension 1994; 23(part 2): 967-70.
36. Traub O, Lloyd MC, Webb RC. Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Cardiovasc Drugs Ther 1995; 9: 421-9.
37. Watts SW, Traub O, Webb RC. Effects of ramipril on contractile oscillations in arteries from genetically hypertensive rats. Clin Exp Hypertens 1994;16:881-98.
38. Traub O, Webb RC. Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats. J Pharmacol Exp Ther 1993; 267: 1503-8.
39. Murray P, Pitt B, Webb RC. Ramipril prevents hypersensitivity to phenylephrine in aorta from streptozotocin-induced diabetic rats. Diabetologia 1994; 37: 664-70.
40. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993; 100: 149-56.
41. Watts SW, Finta KM, Lloyd MC, Storm DS, Webb RC. Enhanced vascular responsiveness to Bay K 8644 in mineralocorticoid- and N-nitro arginine-induced hypertension. Blood Pressure 1994; 3: 340-8.
42. Arnal J, Warin L, Michel J. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 1992; 90: 647-52.
43. Blot S, Arnal J-F, Xu Y, Gray F, Michel J-B. Spinal cord infarcts during long term inhibition of nitric oxide synthesis in rats. Stroke 1994; 25: 1666-73.
44. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994; 12 Suppl 2: S1-5.
45. Erdos EF, Johnson A, Boyden NT. Hydrolysis of enkephalin by cultured endothelial cells and purified dipeptidyl peptidase. Biochem Pharmacol 1978; 27: 843-78.
46. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidai M, Mombouli J-V. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993; 22 Suppl 5: S10-6.
47. De Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85: 2334-8.
48. Vanhoutte PM. State of the Art lecture: endothelium and responsiveness of vascular smooth muscle. J Hypertens 1987; 5 Suppl 5: S115-20.
49. Komori I, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels 1990; 27: 238-45.